

Sulfur Metabolism and Sulfur-Containing Amino Acids Derivatives – II: Autism Spectrum Disorders, Schizophrenia and Fibromyalgia

Lionella Palego^{1*}, Laura Betti² and Gino Giannaccini²

¹Department of Clinical and Experimental Medicine, via Savi 10, University of Pisa, Italy

²Department of Pharmacy, via Bonanno 6, University of Pisa, Pisa, Italy

Abstract

The metabolism of sulfur (S) compounds concurs to the maintain of cell homeostasis and tissue integrity in the human body. Sulfur chemical species act in all cells as anti-oxidant/scavenging agents or regulators of membrane stability/excitability. At the same time, they also exert tissue-dependent functions behaving as protective molecules of the liver and cardiovascular system, as modulators of the immune response, gut activity and CNS neurotransmitter signaling. The involvement of S compounds in human complex, chronic, disabling diseases at multifaceted pathogenesis is actually under investigation: altered levels of S metabolites could be in fact bio-indicators of impaired oxidation state in the body and their unbalance could be risk factors for disease onset. By the present review, we will discuss data from the literature which unearth an altered S biochemistry in human complex illnesses, taking as an example highly invalidating neuropsychiatry and pain perception diseases as autism spectrum disorders (ASD), schizophrenia and fibromyalgia. As well, we will depict herein the utility at applying to this area of the clinical research high resolving -omics strategies in combination with methodological tools which specifically explore S metabolism in patients. The perspectives of these kind of analyses would be the adoption of more valuable, personalized therapeutics protocols and, possibly, an improved bio-monitoring of patients, also including their response to treatments.

Keywords: Sulfur metabolism; Human complex disorders; Autism; Schizophrenia; Fibromyalgia

Introduction

As shown in the first part of this review dedicated to sulfur (S) metabolism in humans, the regulation of the molecular networks involving this element and the metabolic fluxes of S-containing amino acids (Met, Cys, HCys, and Tau) are overall orchestrated by diet, hormones, specific substrates as well as energy metabolism, on the basis of cell/tissue demands, aging and gender-linked factors. Since each S and S-AA biotransformation in humans takes part to numerous, fundamental functions at the interplay between environmental changes and chemical homeostasis, variations of one of the genes coding for enzymes of these paths, in relation to the type of genetic variant, can affect different tissues and anatomical districts or contribute to the pathogenesis of different possible pathological conditions. For instance, the autosomal recessive inherited disorder of transsulfuration characterized by homocystinuria, hyperhomocytinemia and hypermethioninemia due to a genetic defect of cystathionine- β -synthase (CBS), can provoke severe disturbances at the level of the Central Nervous System (CNS), the eye function and vision and/or the musculoskeletal and cardiovascular systems [1]. The second section of this review dedicated to S metabolism in human health deals instead with the possible contribution of unbalanced S biotransformations to human complex disorders, at multi-factorial, in most cases unclear, etiology and pathogenesis. Among complex human diseases, we can find, for instance, type II diabetes, obesity, a variety of cancer types, cardiovascular, neurodegenerative and neuropsychiatry disorders, epilepsy, pain perception, musculoskeletal and autoimmune disorders, as well as the often overlapping irritable bowel and chronic fatigue syndromes. These disorders can rise prenatally or during the early development or being typical diseases of a particular lifespan period, as adolescence or middle age, for instance menopause for women. Thus, it is usually accepted that human complex disorders derive from the interaction of genetic variance and environmental, lifestyle and lifespan factors. The genetic architecture of complex disorders is characterized

by the involvement of multiple genes and/or proteins, differently from single-gene inherited disturbances. Common gene polymorphisms or allelic variants (single nucleotide polymorphisms, SNPs) of more than one gene have been found to concur, as vulnerability factors, to the development of a human complex disease [2,3]. In this last case, it is also possible that allelic variants of a same pleiotropic gene are linked to a number of different, but overlying, disorders, syndromes and altered responses [3,4]. Each gene variant and vulnerability factor involved can subtly and differentially shape phenotypes and traits in complex diseases [2,3]. Beside genetic variance, changed gene/protein expression patterns, epigenetic and metabolic variations in patients vs. controls can underlie state/trait factors of a complex disease [5]. Prevention and treatment of all these chronic and highly invalidating disturbances, at high costs for the whole community even in developing countries, represent main targets in clinical research. We therefore aim at presenting herein the “state-of-the-art” of the actually available data on the reported genetic, epigenetic and metabolic variations concerning S chemistry in patients affected by some among these complex diseases and in particular: the developmental brain autism spectrum disorders (ASD), the high invalidating psychiatric disease schizophrenia and the chronic pain syndrome fibromyalgia. We discuss these results trying to define the possible future perspectives and the methodological approaches to follow in the field.

***Corresponding author:** Lionella Palego, Department of Clinical and Experimental Medicine, via Savi 10, University of Pisa, Italy, Tel: 0039-0502219518/535; Fax: 0039-0502219609; E-mail: lionella.palego@unipi.it

Received: December 15, 2014; **Accepted:** December 30, 2014; **Published:** January 06, 2015

Citation: Palego L, Betti L, Giannaccini G (2015) Sulfur Metabolism and Sulfur-Containing Amino Acids Derivatives – Part II: Autism Spectrum Disorders, Schizophrenia and Fibromyalgia. Biochem Pharmacol (Los Angel) 3: 159. doi:[10.4172/2167-0501.1000159](http://dx.doi.org/10.4172/2167-0501.1000159)

Copyright: © 2015 Palego L et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Autism spectrum disorders

Autism spectrum disorders (ASD), encompassing Autistic Disorder, Asperger's Disorder, and Pervasive Developmental Disorder Not Otherwise Specified (PDDNOS), are characterized by relevant disturbances of the CNS function as impaired social behavior, deficits in emotion perception and non-verbal communication, accompanied by abnormal memory performance as well as disrupted cognitive and learning abilities. Alterations of brain development and CNS function in ASD occur prenatally or during the early childhood [6]. Despite the remarkable number of investigations on ASD, their etiology remains unclear. Genetics plays a major role, as revealed by the high (about 70%) concordance reported in twin studies and other investigations [6-8]. However, accordingly to the high symptoms' variance, DNA investigations have also revealed a strong genetic heterogeneity in ASD, a feature which has contributed to consider them as non uniform genetic disturbances of brain development [9,10]. If common allelic variants have been found prevalent, combination of a rare and common variations or exclusively rare cannot be excluded in ASD, suggesting that gene variants and different protein functionalities underlie clusters of symptoms and dysfunctions. Next to molecular biology investigations, epigenetic and environmental factors of ASD are also receiving the highest consideration: the most currently accepted hypothesis among clinical researchers and neurobiologists is that ASD arise at the interface between vulnerability genes, epigenetic and environmental factors: changes in DNA/histone methylation patterns and altered gene expression are supposed to underlie ASD in the context of genetic vulnerabilities and particular lifestyles [11,12]. The study of S metabolism is part of this research field. Due to its involvement in methylation processes and gene expression, S metabolism has been investigated in wide cohorts of ill children and age-matched controls. Interestingly, altered transmethylation/transsulfuration metabolites together a 50% lower SAM/SAH ratio have been found in serum of autistic children vs. controls, suggesting an unbalanced Met metabolism accompanied by hypomethylation in ASD [13,14]. These studies are also supported by findings of an increased frequency of polymorphisms of Met re-methylation genes in ASD children than controls, such as the MethyleneTetraHydroFolateReductase (MTHFR) 677C>T one which reduces the activity of this enzyme [15]. Other studies have reported lower circulating levels of GSH, Met and Cys, together increased levels of GSSG, the oxidized form of glutathione, in ill children [16-19], suggesting an impaired oxidative stress in autism disorders. The reduced ratio GSH:GSSG in ASD patients is a finding replicated in many studies, in blood or post-mortem brain using different technologies as HPLC, gas chromatography and others [16,20]. Moreover, impaired methylation capacity and altered circulating levels of HCys have been observed in autistic children and in their parents [21]. Either higher or lower HCys levels have been found in ASD or a different involvement of folate metabolism genes, implying the need to further investigate Met metabolism in these disorders and the possible presence of family clusters [15,21-24]. The immunological unbalance as well as dysbiosis and gut malfunction observed in autism [25,26] can derive from the reported changes in Met pathways. Mitochondrial defects have been also observed in ASD, further sustaining the role of oxidative metabolism in their pathogenetic mechanisms, accompanied by an impairment of pro-oxidant/anti-oxidant activities [27]. In addition, an impaired sulfotransferase (ST) detoxification capacity has been reported in ASD and genetic variants of ST Isoforms, the SULT1a, have been associated with autism [28]. Impaired sulfoconjugation and, as a consequence, an altered catecholamine catabolism, including catechol-O-methyl-transferase (COMT) variants with altered

activity, can affect noradrenergic and 5-HT cross-talks. It is worth noting that 5-HT levels have been found consistently increased in platelets of about 40% children with ASD, another among the most replicated biochemical features in biological studies concerning these disorders [29]. Hyperserotoninemia in autism can be explained by a polymorphism in the promoter region of the gene of the 5-HT transporter, at least in family clusters [30], but concurrent events are not avoided. Altered sulfation in autism can be even enhanced by the increased SO_4^{2-} excretion observed in children with a diagnosis of autism, a finding related to the increased oxidative stress or to genetics features [31]. Sulfation seems in fact to play a main role during fetal development [32]. As well, some plasma AAs have been found altered in children with ASD [33,34].

The ASD neurochemistry is thus defined by heterogeneous genetic and epigenetic vulnerabilities: these can result in platelet hyperserotoninemia, impaired Met and folate metabolism, DNA hypomethylation and, possibly, gene expression up-regulation, increased oxidative stress and altered AA plasma profile; these dysfunctions can be present at different degrees, defining clusters of symptoms and phenotypes and the severity of the illness.

Schizophrenia and psychosis

Schizophrenia, a devastating behavioral disease, is characterized by delusions, thought disorder, hallucinations, psychosis and cognitive deficits. Schizophrenia affects the most basic human processes of perception, emotion and judgment at different degrees of severity [35]. As for autism, genetics studies of schizophrenia have shown heterogeneous and complex profiles, suggesting that the disease could originate from common and rare variants, but also from epigenetics alterations [36]. Beside the dopaminergic/serotonin hypothesis, other biochemical substrates are supposed to underlie schizophrenia and psychosis. As regards the topic of this review, an old story relates S-AAs, Met biochemistry and schizophrenia: in the early '60s, some authors observed that administration of Met together monoaminoxidase inhibitors (MAOI) worsened symptoms in schizophrenic patients [37,38]. Since that time, after a long period of disregard, a renovated interest is now emerging on Met pathways in neuropsychiatric disorders, depression, delusion and negative symptoms of psychotic-related disorders and schizophrenia. First, genetic studies have involved genes of S biochemistry as vulnerability factors of the disease and a genetic hypothesis underlying psychosis and altered HCys metabolism has been also formulated [39]. Differently from autism, schizophrenic and bipolar psychotic patients characterized by Met metabolism dysfunction, consistently show elevated HCys plasma levels [40,41]. Moreover, as a risk factor to develop the disease, changes and variants of the 1 C cycle enzymes have been reported: in particular, as for ASD, the HCys remethylation enzyme MTHFR 677C>T has been linked to psychotic behavior [42-44]. Other S-related genes have been implicated in schizophrenia, as DNA variation of SULT4a1, a sulfotransferase isoform expressed in the brain only which specifically promotes sulfation of catecholamine [45], or Met sulfone reductase [46]. Plasma levels studies have linked variation of plasma S-AAs as Met and Cys to different phases of this invalidating mental illness: for instance, Met was found lower in psychotic patients unresponsive to atypical antipsychotic drugs, whereas high Met was reported in drug-free patients with schizophrenia. Others have shown low S-AAs levels in psychosis. Finally, some authors have reported that an altered plasma Tau/Met-Ser ratio can be a powerful biomarker of acute psychosis [47]. Investigations on platelet STs in patients with mood disorders have shown an increased enzyme activity in bipolar disorder [48]. These

data, albeit in part discordant, suggest an imbalance of S metabolism in psychosis and schizophrenia. As aforementioned, a number of studies have reported increased circulating levels of HCys in schizophrenic and bipolar patients [49,50]. High HCys in schizophrenia has been related to the above reported genetic variations, but several new findings are also in support of epigenetic causes. The amount of HCys in tissues and blood depends from Met metabolism balance and, in particular, from the relative activities of Met transmethylation and remethylation enzymes, regulated by the intake of folic acid and B group vitamins. High circulating levels of HCys have been related not only to neuropsychiatric disorders but also to cardiovascular diseases, diabetes and neurodegenerative diseases, indicating that its metabolism exert pleiotropic effects in the body. An interesting finding has shown the significant reduction of transthyretin, a protein transporter of the circulating thyroid hormone T4 and retinol, in psychosis [51]. Since HCys reduces the active form of transthyretin [52], cognitive impairment in psychosis and schizophrenia could be linked to high HCys levels and low transthyretin. The hypothesis formulated by Costa and coauthors starts instead from the early Met studies on schizophrenia and relates these findings to an hypermethylation of specific genes, provoking their down-regulation, in schizophrenic patients [53,54]. The susceptibility seems linked to gender variables [54]. Interestingly, Met metabolism and dopamine transmission have been found interlaced in schizophrenia, a finding needing replication [55]. Thus, schizophrenia and psychosis are characterized by heterogeneous genetics and, at a different degree, by dopamine/monoamine imbalance, altered sulfation, S metabolism changes and, possibly, hypermethylation, gene expression down-regulation patterns and transthyretin deficit. Mitochondrial dysfunctions are also emerging [56].

Fibromyalgia

The metabolism of S, Met and other S-AAs has been extensively investigated in rheumatic diseases and osteoarthritis. Herein, we will call rather attention on unspecified muscle pain disorders as fibromyalgia. This syndrome is characterized by a constellation of pain symptoms and overlap with neuropsychiatric and gastrointestinal diseases [57]. Despite being one of the most frequent diagnoses in clinical rheumatology practice, fibromyalgia etiology and pathogenesis remain elusive. Fibromyalgia syndrome has been related to disturbances of the hypothalamic-pituitary axis and neurotransmission defects, involving excitatory amino acids, catecholamines, substance P and 5-HT [58-60]: patient's symptoms may derive from poor stressor modulation, sensitization of specific nociceptor neurons and pain threshold diminution in response to multiple environmental factors, such as mechanical or emotional trauma, chronic stress or even infections. In substance, all patients with fibromyalgia, in high prevalence women, report a diminished pain perception threshold together a greater vulnerability to diverse stressors. Concerning the role of S metabolism, its indirect involvement in this syndrome is supported by the clinical efficacy of oral administrations of SAM (Samyr) reported in patients with fibromyalgia [61]. This has been mainly ascribed to the fact that SAM is a methyl donor in epinephrine or melatonin formation, two molecules involved in sleep-arousal regulation and mood/anxiety tonus [62], frequently altered in patients with fibromyalgia. Despite treatment with SAM is effective in fibromyalgia, relatively few studies have been conducted on S metabolism in this field of medical pathology. Significantly lower levels of ATP, a trend toward higher Ca²⁺ and Mg²⁺ content in platelets as well as markedly reduced plasma levels of S-AAs Met and Tau, together low phenylalanine and tyrosine, the precursor of catecholamines and thyroid hormones, have been obtained in patients

with fibromyalgia vs. healthy control subjects [63-65]. Intestine malabsorption could be a cause of the observed reduction of plasma AAs in patients, this accompanied by gut microbiome alteration and disbiosis [66]. Epigenetic alteration and changes in methylation patterns are also emerging in fibromyalgia [67].

These results, albeit preliminary, are in support of an imbalance of S, catecholamine and purinergic metabolism in patients with fibromyalgia. These results can be ascribed to a concomitant increased oxidative stress in patients with fibromyalgia, as supported by some authors: in fact, in other studies, lower serum levels of catalase and GSH have been found in serum of fibromyalgic subjects [68].

Sulfur, diet and human complex diseases

Nutritional aspects cannot be underestimated when investigating S metabolism in ASD, schizophrenia and fibromyalgia, where a genetic and epigenetic impact has been reported. Diet and biological research on these three complex diseases are the two faces of a same medal: on one side, the nutritional profile of patients should be monitored since diet can alter results on the search of metabolic disturbances in patients, especially those regarding plasma/cell levels of S-compounds or oxidative stress biomarkers in patients. On the other side, the appraisal of patients' nutritional state is part of the disease itself, since stressors or other triggering factors can influence feeding behavior in vulnerable subjects, provoking nutritional and metabolic deficits. In some individuals, vulnerable genes are even directly implicated in the metabolic processes altered by an unbalanced diet, enhancing therefore some symptom features rather than others.

A normal, equilibrated diet, along with a good supply of proteins, gives the required amount of S. However, the complexity of S metabolism and its regulation makes difficult to define its real requirement for health care in different lifespan stages and pathological conditions [69]. Moreover, Met metabolism is dependent of vitamins and essential cofactors: thus, it is evident that diet can strongly influence S-compounds' metabolism in the body [70,71]. Stressors, low stress coping, low-quality lifestyle, drug abuse, alcoholism and stress-related pathologies potentially lead to incorrect alimentary choices/habits and even taste changes [72]. Unbalanced diet can affect methylation patterns and epigenomics [73,74]. The recommended daily allowance (RDA) suggests to ingest at least 13 mg Kg⁻¹ body weight per day of S, but other sources contrast these values and recommend daily doses \geq 20 mg Kg⁻¹ body weight. Some authors have reported that the different stages of the life span require variable S assumption from diet [75]. On the other side, some authors have reported that Met diet restriction increases GSH intra-cell levels and lifespan in mouse strains through feed-back adaptation mechanisms [76]. Therefore, additional investigation would provide an improved understanding of factors determining S and S-AAs bioavailability in healthy subjects and patients.

Sulfur metabolism and -Omics techniques in ASDs, schizophrenia and fibromyalgia

The study of S-AA metabolism is carried out through specific isotope tracers taken by S compounds [77]. Furthermore, the development of high-resolving techniques as HPLC coupled to UV or electrochemical and fluorescence detection has improved the study of S metabolites in body fluids or cells [78]. A valuable, specific and sensitive measurement of S-AAs, GSH/GSSG ratio, SAM/SAH ratio can in fact provide useful information on cell redox state, DNA methylation and Met metabolism. On the other side, a multi-factorial approach is thus the most suitable, implying the identification of clusters and groups of


patients within a pathological condition, presumably showing distinct biochemistry patterns, symptoms or responses to treatment. Database can be evaluated through suitable multivariate statistical analysis, including cluster and principal component analysis. Recognizing the existence of biochemical clusters within schizophrenia and fibromyalgia could further support the notion that these disorders are not “single”, “fixed” pathological entities but rather spectrum disorders.

The new emerging -omics technologies are, by now, the best approach to investigate biological correlates of complex, chronic and invalidating disorders as ASDs, schizophrenia and fibromyalgia, permitting to monitor the numerous disease’s variables. These techniques offers a “full screen” vision of patients’ biology, consisting in DNA array genomic/transcriptomic/methylomic analyses, in the proteomic evaluation of all expressed proteins as well as the measure of metabolites, substrates (metabolomics) and drug levels in cells, tissues or body fluids of patients during the different phases of the disease and pharmacological therapy. Proteomics and metabolomics apply LC/MS-MS techniques which enable the measurement of numerous proteins and substrates. Hyphenated HP-LC techniques are also improving resolution in the field [79].

If a main obstacle to these investigations consists in the high-costs, this can be circumvented by the participation into multicenter laboratory studies. The-omics tool permits to simultaneously investigate multiple, potentially involved molecular mechanisms and

systems in cells and tissues, from DNA to metabolic substrates. As an example, Figure 1 is a schematic representation of those molecular substrates and factors potentially underlying ASD, schizophrenia and fibromyalgia together the presumed triggering genetic, epigenetic and environmental variables.

For -omics investigations, the analysis of body fluids as blood, serum, plasma, saliva or peripheral cell models as circulating lymphomonocytes, platelets or erythrocytes and tissue autopsy, can be integrated with the traditional protein specific assays and/or post-mortem/animal studies which apply to the search of a single or few specific biomarkers. In the case of S metabolism, specific evaluation consists, as indicated before, in the search of changes of Met metabolites as HCys in body fluids. Applying -omics techniques would permit to characterize specific S metabolic profiles also targeting disease’s genetic/epigenetic, redox imbalance in human disorders as well as pharmacological treatment by drug metabolism evaluation and patient response to treatments. This approach endows with a robust, powerful tool of investigation of complex disorders as ASD, schizophrenia and fibromyalgia. New relationships between metabolic paths and systems could be found, providing signatures, maps and pathophysiological networks. In autism research, proteomics and metabolomics are leading towards new diagnostic and therapeutic perspectives [80-82]. The same is occurring for schizophrenia [83,84] or fibromyalgia [85,86]. Application of -omics strategies in these diseases have also



involved the therapeutic monitoring of pharmacological response [87], nutritional aspects and microbioma evaluation [88].

Conclusion

The targeting of S biology represents a main issue in human pathology which could be better defined through a multidisciplinary approach, encompassing molecular biology, biochemical, pharmacological, nutritional and statistical evaluations. The -omics tool can be a winning strategy to monitor impaired metabolic redox states, networks and patterns in complex, chronic and invalidating human diseases as ASD, schizophrenia and fibromyalgia, even coupled to specific S metabolism evaluations. This would permit to know more about their pathogenesis, possibly permitting to apply personalized therapies. The understanding of redox/ROS modulation mechanisms in cells and tissues and their manipulation would represent a main goal in molecular pathology and treatment of a variety of human diseases. The role of transsulfuration enzymes, their regulation and H₂S formation should be further evaluated as well as metallothioneins and mitochondrial proteins. This approach could help to understand the almost unclear etiology of these diseases, as well as to detect clusters of symptoms and biochemical changes in these disorders, improving pharmacological investigations.

References

- Picker JD, Levy HL (2004) Homocystinuria caused by Cystathionine Beta-Synthase Deficiency. In: Pagon RA, Adam MP, Ardinger HH, Bird TD, Dolan CR, et al. (eds) *Gene reviews*. University of Washington, Seattle, USA.
- Rzhetsky A, Wajngurt D, Park N, Zheng T (2007) Probing genetic overlap among complex human phenotypes. *Proc Natl Acad Sci U S A* 104: 11694-11699.
- Stranger BE, Stahl EA, Raj T (2011) Progress and promise of genome-wide association studies for human complex trait genetics. *Genetics* 187: 367-383.
- Sivakumaran S, Agakov F, Theodoratou E, Prendergast JG, Zgaga L, et al. (2011) Abundant pleiotropy in human complex diseases and traits. *Am J Hum Genet* 89: 607-618.
- Jais PH (2005) How frequent is altered gene expression among susceptibility genes to human complex disorders? *Genet Med* 7: 83-96.
- Lord C, Cook EH, Leventhal BL, Amaral DG (2000) Autism spectrum disorders. *Neuron* 28: 355-363.
- Keller F, Persico AM (2003) The neurobiological context of autism. *Mol Neurobiol* 28: 1-22.
- Geschwind DH (2011) Genetics of autism spectrum disorders. *Trends Cogn Sci* 15: 409-416.
- Glessner JT, Wang K, Cai G, Korvatska O, Kim CE, et al. (2009) Autism genome-wide copy number variation reveals ubiquitin and neuronal genes. *Nature* 459: 569-573.
- Gaugler T, Klei L, Sanders SJ, Bodea CA, Goldberg AP, et al. (2014) Most genetic risk for autism resides with common variation. *Nat Genet* 46: 881-885.
- Tordjman S, Somogyi E, Coulon N, Kermarrec S, Cohen D, et al. (2014) Gene×Environment interactions in autism spectrum disorders: role of epigenetic mechanisms. *Front Psychiatry* 5: 53.
- Herbert MR (2010) Contributions of the environment and environmentally vulnerable physiology to autism spectrum disorders. *Curr Opin Neurol* 23: 103-110.
- James SJ, Cutler P, Melnyk S, Jernigan S, Janak L, et al. (2004) Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. *Am J Clin Nutr* 80: 1611-1617.
- Frustaci A, Neri M, Cesario A, Adams JB, Domenici E, et al. (2012) Oxidative stress-related biomarkers in autism: systematic review and meta-analyses. *Free Radic Biol Med* 52: 2128-2141.
- James SJ, Melnyk S, Jernigan S, Cleves MA, Halsted CH, et al. (2006) Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism. *Am J Med Genet B Neuropsychiatr Genet* 141B: 947-956.
- Hartzell S, Seneff S (2012) Impaired sulfate metabolism and epigenetics: is there a link in autism? *Entropy* 14: 1953-1977.
- Waring RH, Klovzra LV (2000) Sulphur metabolism in autism. *J Nutr Environm Med* 10: 25-32.
- Main PA, Angley MT, Thomas P, O'Doherty CE, Fenech M (2010) Folate and methionine metabolism in autism: a systematic review. *Am J Clin Nutr* 91: 1598-1620.
- Geier DA, Kern JK, Garver CR, Adams JB, Audhya T, et al. (2009) A prospective study of transsulfuration biomarkers in autistic disorders. *Neurochem Res* 34: 386-393.
- Chauhan A, Audhya T, Chauhan V (2012) Brain region-specific glutathione redox imbalance in autism. *Neurochem Res* 37: 1681-1689.
- James SJ, Melnyk S, Jernigan S, Hubanks A, Rose S, et al. (2008) Abnormal transmethylation/transsulfuration metabolism and DNA hypomethylation among parents of children with autism. *J Autism Dev Disord* 38: 1966-1975.
- Paşca SP, Dronca E, Kaucsár T, Craciun EC, Endreffy E, et al. (2009) One carbon metabolism disturbances and the C677T MTHFR gene polymorphism in children with autism spectrum disorders. *J Cell Mol Med* 13: 4229-4238.
- Kaluźna-Czaplińska J, Żurawicz E, Michalska M, Rynkowski J (2013) A focus on homocysteine in autism. *Acta Biochim Pol* 60: 137-142.
- Sener EF, Oztop DB, Ozkul Y (2014) MTHFR Gene C677T Polymorphism in Autism Spectrum Disorders. *Genet Res Int* 2014: 698574.
- Onore C, Careaga M, Ashwood P (2012) The role of immune dysfunction in the pathophysiology of autism. *Brain Behav Immun* 26: 383-392.
- Williams BL, Hornig M, Timothy B., Bauman ML, Cho Paik M, et al. (2011) Impaired Carbohydrate Digestion and Transport and Mucosal Dysbiosis in the Intestines of Children with Autism and Gastrointestinal Disturbances. *PlosOne*. 6: e24585
- Palmieri L, Persico AM (2010) Mitochondrial dysfunction in autism spectrum disorders: cause or effect? *Biochim Biophys Acta* 1797: 1130-1137.
- Kumar RA, KaraMohamed S, Sudi J, Conrad DF, Brune C, et al. (2008) Recurrent 16p11.2 microdeletions in autism. *Hum Mol Genet* 17: 628-638.
- Burgess NK, Sweeten TL, McMahon WM, Fujinami RS (2006) Hyperserotonemia and altered immunity in autism. *J Autism Dev Disord* 36: 697-704.
- Yirmiya N, Pilowsky T, Nemanov L, Arbelle S, Feinsilver T, et al. (2001) Evidence for an association with the serotonin transporter promoter region polymorphism and autism. *Am J Med Genet* 105: 381-386.
- Bowling FG, Heussler HS, McWhinney A, Dawson PA (2013) Plasma and urinary sulfate determination in a cohort with autism. *Biochem Genet* 51: 147-153.
- Richard K, Hume R, Kaptein E, Stanley EL, Visser TJ, et al. (2001) Sulfation of Thyroid Hormone and Dopamine during Human Development: Ontogeny of Phenol Sulfotransferases and Arylsulfatase in Liver, Lung, and Brain. *J Clin Endocrinol Metab* 86: 2734-2742.
- Ghanizadeh A (2013) Increased glutamate and homocysteine and decreased glutamine levels in autism: a review and strategies for future studies of amino acids in autism. *Dis Markers* 35: 281-286.
- Naushad SM, Jain JM, Prasad CK, Naik U, Akella RR (2013) Autistic children exhibit distinct plasma amino acid profile. *Indian J Biochem Biophys* 50: 474-478.
- Ross CA, Margolis RL, Reading SA, Pletnikov M, Coyle JT (2006) Neurobiology of schizophrenia. *Neuron* 52: 139-153.
- Abdolmaleky HM, Thiagalingam S, Wilcox M (2005) Genetics and epigenetics in major psychiatric disorders: dilemmas, achievements, applications, and future scope. *Am J Pharmacogenomics* 5: 149-160.
- Pollin W, Cardon PV Jr, Kety SS (1961) Effects of amino acid feedings in schizophrenic patients treated with iproniazid. *Science* 133: 104-105.
- Cohen SM, Nichols A, Wyatt R, Pollin W (1974) The administration of methionine to chronic schizophrenic patients: a review of ten studies. *Biol Psychiatry* 8: 209-225.

39. Muntjewerff JW, Kahn RS, Blom HJ, den Heijer M (2006) Homocysteine, methylenetetrahydrofolate reductase and risk of schizophrenia: a meta-analysis. *Mol Psychiatry* 11: 143-149.
40. Smithies J (2012) The role of abnormalities related to the one carbon cycle in depression and schizophrenia. *Neurosci & Schiz* 3: 101-106.
41. Osher Y, Sela BA, Levine J, Belmaker RH (2004) Elevated homocysteine levels in euthymic bipolar disorder patients showing functional deterioration. *Bipolar Disord* 6: 82-86.
42. Dietrich-Muszalska A, Malinowska J, Olas B, Glowacki R, Bald E, et al. (2012) The oxidative stress may be induced by the elevated homocysteine in schizophrenic patients. *Neurochem Res* 37: 1057-1062.
43. Kempisty B, Mostowska A, Górska I, Łuczak M, Czerni P, et al. (2006) Association of 677C>T polymorphism of methylenetetrahydrofolate reductase (MTHFR) gene with bipolar disorder and schizophrenia. *Neurosci Lett* 400: 267-271.
44. Brustolin S, Giugliani R, Félix TM (2010) Genetics of homocysteine metabolism and associated disorders. *Braz J Med Biol Res* 43: 1-7.
45. Meltzer HY, Brennan MD, Woodward ND, Jayathilake K (2008) Association of Sult4A1 SNPs with psychopathology and cognition in patients with schizophrenia or schizoaffective disorder. *Schizophr Res* 106: 258-264.
46. Walss-Bass C, Soto-Bernardini MC, Johnson-Pais T, Leach RL, Ontiveros A, et al. (2009) Methionine Sulfoxide reductase: a novel schizophrenia candidate gene. *Am J Med Genet B Neuropsychiatr Genet* 150B: 219-225.
47. De Luca V, Viggiano E, Messina G, Viggiano A, Borlido C, et al. (2008) Peripheral amino acid levels in schizophrenia and antipsychotic treatment. *Psychiatry Investig* 5: 203-208.
48. Marazziti D, Palego L, Dell'Osso L, Batistini A, Cassano GB, et al. (1996) Platelet sulfotransferase in different psychiatric disorders. *Psychiatry Res* 65: 73-78.
49. Applebaum J, Shimon H, Sela BA, Belmaker RH, Levine J (2004) Homocysteine levels in newly admitted schizophrenic patients. *J Psychiatr Res* 38: 413-416.
50. Ayesa-Arriola R, Pérez-Iglesias R, Rodríguez-Sánchez JM, Mata I, Gómez-Ruiz E, et al. (2012) Homocysteine and cognition in first-episode psychosis patients. *Eur Arch Psychiatry Clin Neurosci* 262: 557-564.
51. Huang JT, Leweke FM, Oxley D, Wang L, Harris N, et al. (2006) Disease biomarkers in cerebrospinal fluid of patients with first-onset psychosis. *PLoS Med* 3: e428.
52. Hanyu N, Shimizu T, Yamauchi K, Okumura N, Hidaka H (2009) Characterization of cysteine and homocysteine bound to human serum transthyretin. *Clin Chim Acta* 403: 70-75.
53. Costa E, Chen Y, Davis J, Dong E, Noh JS, et al. (2002) REELIN and schizophrenia: a disease at the interface of the genome and the epigenome. *Mol Interv* 2: 47-57.
54. Shimabukuro M, Sasaki T, Imamura A, Tsujita T, Fuke C, et al. (2007) Global hypomethylation of peripheral leukocyte DNA in male patients with schizophrenia: a potential link between epigenetics and schizophrenia. *J Psychiatr Res* 41: 1042-1046.
55. Sharma A, Kramer ML, Wick PF, Liu D, Chari S, et al. (1999) D4 dopamine receptor-mediated phospholipid methylation and its implications for mental illnesses such as schizophrenia. *Mol Psychiatry* 4: 235-246.
56. Prabakaran S, Swatton JE, Ryan MM, Huffaker SJ, Huang JT, et al. (2004) Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. *Mol Psychiatry* 9: 684-697, 643.
57. Rahman A, Underwood M, Carnes D (2014) Fibromyalgia. *BMJ* 348: g1224.
58. Neeck G, Crofford LJ (2000) Neuroendocrine perturbations in fibromyalgia and chronic fatigue syndrome. *Rheum Dis Clin North Am* 26: 989-1002.
59. Lyon P, Cohen M, Quintner J (2011) An evolutionary stress-response hypothesis for chronic widespread pain (fibromyalgia syndrome). *Pain Med* 12: 1167-1178.
60. Bazzichi L, Giannaccini G, Betti L, Mascia G, Fabbri L, et al. (2006) Alteration of serotonin transporter density and activity in fibromyalgia. *Arthritis Res Ther* 8: R99.
61. Tavoni A, Jeracitano G, Cirigliano G (1998) Evaluation of S-adenosylmethionine in secondary fibromyalgia: a double-blind study. *Clin Exp Rheumatol* 16: 106-107.
62. Kim JS, Coon SL, Blackshaw S, Cepko CL, Møller M, et al. (2005) Methionine adenosyltransferase:adrenergic-cAMP mechanism regulates a daily rhythm in pineal expression. *J Biol Chem* 280: 677-684.
63. Bazzichi L, Rossi A, Giuliano T, De Feo F, Giacomelli C, et al. (2007) Association between thyroid autoimmunity and fibromyalgic disease severity. *Clin Rheumatol* 26: 2115-2120.
64. Bazzichi L, Palego L, Giannaccini G, Rossi A, De Feo F, et al. (2009) Altered amino acid homeostasis in subjects affected by fibromyalgia. *Clin Biochem* 42: 1064-1070.
65. Bazzichi L, Giannaccini G, Betti L, Fabbri L, Schmid L, et al. (2008) ATP, calcium and magnesium levels in platelets of patients with primary fibromyalgia. *Clin Biochem* 41: 1084-1090.
66. Şimşek I (2011) Irritable bowel syndrome and other functional gastrointestinal disorders. *J Clin Gastroenterol* 45 Suppl: S86-88.
67. Menzies V, Lyon DE, Archer KJ, Zhou Q, Brumelle J, et al. (2013) Epigenetic alterations and an increased frequency of micronuclei in women with fibromyalgia. *Nurs Res Pract* 2013: 795784.
68. Sendur OF, Turan Y, Tastaban E, Yenisey C, Serter M (2009) Serum antioxidants and nitric oxide levels in fibromyalgia: a controlled study. *Rheumatol Int* 29: 629-633.
69. Parcell S (2002) Sulfur in human nutrition and applications in medicine. *Altern Med Rev* 7: 22-44.
70. Adams JB, Audya T, McDonough-Means S, Rubin RA, Quig D, et al. (2011) Nutritional and metabolic status of children with autism vs. neurotypical children and the association with autism severity. *Nutr & Metabol* 8: 34.
71. Sugden C (2006) One-carbon metabolism in psychiatric illness. *Nutr Res Rev* 19: 117-136.
72. Oliver G, Wardle J, Gibson EL (2000) Stress and food choice: a laboratory study. *Psychosom Med* 62: 853-865.
73. Bottiglieri T (2002) S-Adenosyl-L-methionine (SAME): from the bench to the bedside--molecular basis of a pleiotropic molecule. *Am J Clin Nutr* 76: 1151S-7S.
74. Choi SW, Friso S (2010) Epigenetics: A New Bridge between Nutrition and Health. *Adv Nutr* 1: 8-16.
75. Nimni ME, Han B, Cordoba F (2007) Are we getting enough sulfur in our diet? *Nutr Metab (Lond)* 4: 24.
76. Richie JP Jr, Leutzinger Y, Parthasarathy S, Malloy V, Orentreich N, et al. (1994) Methionine restriction increases blood glutathione and longevity in F344 rats. *FASEB J* 8: 1302-1307.
77. MacCoss MJ, Fukagawa NK, Matthews DE (2001) Measurement of intracellular sulfur amino acid metabolism in humans. *Am J Physiol Endocrinol Metab* 280: E947-955.
78. Persichilli S, Gervasoni J, Castagnola M, Zuppi C, Zappacosta B (2011) A Reversed-Phase HPLC Fluorimetric Method for Simultaneous Determination of Homocysteine-Related Thiols in Different Body. *Fluids Lab Medicine* 42: 657-662.
79. Patel KN, Patel JK, Patel MP, Rajput GC, Patel HA (2010) Introduction to hyphenated techniques and their applications in pharmacy. *Pharm Methods* 1: 2-13.
80. Al-Ayadhi L, Halepoto DM (2013) Role of proteomics in the discovery of autism biomarkers. *J Coll Physicians Surg Pak* 23: 137-143.
81. Momeni N, Bergquist J, Brudin L, Behnia F, Sivberg B, et al. (2012) A novel blood-based biomarker for detection of autism spectrum disorders. *Transl Psychiatry* 2: e91.
82. Wetie AG, Dekroon RM, Mocanu M, Ryan JP, Darie CC, et al. (2014) Mass spectrometry for the study of autism and neurodevelopmental disorders. *Adv Exp Med Biol* 806: 525-544.
83. Alawam K (2014) Application of proteomics in diagnosis of ADHD, schizophrenia, major depression, and suicidal behavior. *Adv Protein Chem Struct Biol* 95: 283-315.

84. Orešič M, Tang J, Seppanen-Laakso T, Mattila I, Saarni SE, et al. (2011) Metabolome in schizophrenia and other psychotic disorders: a general population-based study. *Genome Med* 3: 19.
85. Bazzichi L, Ciregia F, Giusti L, Baldini C, Giannaccini G, et al. (2009) Detection of potential markers of primary fibromyalgia syndrome in human saliva. *Proteomics Clin Appl* 3: 1296-1304.
86. Caboni P, Liori B, Kumar A, Santoru ML, Asthana S, et al. (2014) Metabolomics analysis and modeling suggest a lysophosphocholines-PAF receptor interaction in fibromyalgia. *PLoS One* 9: e107626.
87. Kaddurah-Daouk R, Kristal BS, Weinshilboum RM (2008) Metabolomics: a global biochemical approach to drug response and disease. *Annu Rev Pharmacol Toxicol* 48: 653-683.
88. Gibney MJ, Walsh M, Brennan L, Roche HM, German B, et al. (2005) Metabolomics in human nutrition: opportunities and challenges. *Am J Clin Nutr* 82: 497-503.

Citation: Palego L, Betti L, Giannaccini G (2015) Sulfur Metabolism and Sulfur-Containing Amino Acids Derivatives – Part II: Autism Spectrum Disorders, Schizophrenia and Fibromyalgia. *Biochem Pharmacol (Los Angel)* 3: 159. doi:[10.4172/2167-0501.1000159](https://doi.org/10.4172/2167-0501.1000159)

Submit your next manuscript and get advantages of OMICS Group submissions

Unique features:

- User friendly/feasible website-translation of your paper to 50 world's leading languages
- Audio Version of published paper
- Digital articles to share and explore

Special features:

- 350 Open Access Journals
- 35,000 editorial team
- 21 days rapid review process
- Quality and quick editorial, review and publication processing
- Indexing at PubMed (partial), Scopus, EBSCO, Index Copernicus and Google Scholar etc
- Sharing Option: Social Networking Enabled
- Authors, Reviewers and Editors rewarded with online Scientific Credits
- Better discount for your subsequent articles

Submit your manuscript at: <http://www.omicsonline.org/submission>

